Most Favored Nation (MFN) pricing is dominating boardroom conversations, and with 26 manufacturers now signed on to MFN agreements, the headlines are hard to ignore. Before you adjust launch sequencing, reprice assets, or pull back from markets, our Market Access Strategy experts pose a harder question: “Under what conditions would MFN pricing actually have a material commercial impact?”

In this new whitepaper, Lumanity’s Moira Ringo, Caroline Solon, Lisa Cashman, and Jonathan Toft break down three structural factors that could significantly limit MFN’s practical reach and what manufacturers should actually be doing to plan with clarity.

Inside, you’ll learn:

    • Why most branded drug revenue may be exempt from MFN
    • Why the timing of MFN price application is far more limited than assumed
    • Why delaying or declining to launch in ex-US markets to “protect” US prices carries major drawbacks beyond revenue

Fill out the form on the right to download the whitepaper.

Download the whitepaper

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Sign me up to receive regular insights from Lumanity
By selecting this box, I consent to receive Lumanity marketing communications by email.